Crescent Biopharma (CBIO) vs Climb Bio (CLYM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Climb Bio (CLYM) has outperformed Crescent Biopharma (CBIO) over the past year, gaining 440.6% versus a loss of 0.5%. Over five years, CLYM leads with a -33.2% price change compared with -92.7% for CBIO. Crescent Biopharma is the larger company by market cap ($543.2 million vs $539.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CBIO | CLYM |
|---|---|---|
| Share price | $13.00 | $9.19 |
| Market cap | $543.21M | $539.80M |
| 1-day change | +0.70% | -0.97% |
| YTD return | +9.61% | +129.75% |
| 1-year return | -0.46% | +440.59% |
| 5-year return | -92.74% | -33.21% |
| EPS (TTM) | $-7.29 | $-0.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $10.84M | — |
| Net income (latest FY) | $-153.94M | $-59.85M |
| Operating margin | -1407.52% | — |
| Net margin | -1419.61% | — |
| 52-week high | $27.41 | $18.33 |
| 52-week low | $8.72 | $1.64 |
| Distance from 52-week high | -52.57% | -49.86% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +148.69% | +209.03% |
| Average volume | 361.17K | 1.38M |
| Shares outstanding | 38.90M | 58.74M |
| Employees | 80 | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLYM has outperformed CBIO by 441.0 percentage points over the past year.
About Crescent Biopharma
CBIO stock →Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
About Climb Bio
CLYM stock →Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
CBIO vs CLYM FAQ
Which is bigger, Crescent Biopharma or Climb Bio?
Crescent Biopharma (CBIO) is larger, with a market capitalization of $543.21M compared with $539.80M for Climb Bio (CLYM).
Which stock has performed better over the past year, CBIO or CLYM?
CLYM returned +440.59% over the past 12 months, compared with -0.46% for CBIO (price return, excluding dividends). Past performance does not predict future results.
Are Crescent Biopharma and Climb Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.